![]() ![]() “The issue is not merely of providing affordable drugs to patients in India, but also to patients in other countries, as India is the source of generic drugs to over hundred countries. ![]() “We fought for patients' rights in this litigation, and we are greatly relieved that the Court has ruled in our favour, and recognised that patients need protecting more than patents,” said Y. All of Novartis’ claims were rejected by the High Court. Novartis claimed that India’s Patents Act did not comply with the TRIPS Agreement and was in violation of the Indian Constitution. Novartis took the Indian government and cancer patients to court over critical public health safeguards included in the 2005 amendments to India’s Patent law. Mumbai/New Delhi, 7 August 2007 – The landmark decision by the Madras High Court upholding India’s Patents Act in the face of the challenge by Swiss pharmaceutical company Novartis is a major victory for patients’ access to affordable medicines in developing countries, stated the Cancer Patients Aid Association (CPAA), the Lawyers Collective HIV/AIDS Unit, the Delhi Network for Positive People (DNP+) and international medical humanitarian organisation Médecins Sans Frontières (MSF). Joint Statement by CPAA, MSF, DNP+ and Lawyers Collective on Novartis Judgment the Cancer Patients Aid Association (CPAA), the Lawyers Collective HIV/AIDS Unit, the Delhi Network for Positive People (DNP+) and Médecins Sans Frontières.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |